

Fig. 3. Comparison of the cumulative occurrence of lamivudine resistance between patients who showed hepatitis B virus (HBV) DNA levels of less than the detection limit (2.6 log copy/ml) at 6 months after starting lamivudine administration and those who did not (left figure), and similarly between patients who showed HBV core-related antigen (HBVcrAg) levels of less than 4.7 log U/ml and those who did not (right figure).

coded by the core gene of the HBV genome with high sensitivity and a wide quantitative range. Serum HBVcrAg levels reflect the viral load in the natural course because these levels correlate linearly with those of HBV DNA (14, 15). On the other hand, the character of HBVcrAg is somewhat different from that of HBV DNA in patients undergoing anti-viral therapies such as lamivudine. That is, HBVcrAg levels decrease significantly more slowly than those of HBV DNA after the initiation of lamivudine administration.

HBV is an enveloped DNA virus containing a relaxed circular DNA genome, which is converted into a covalently closed circular DNA (cccDNA) episome in the nucleus of infected cells (18, 21–23). The cccDNA molecules serve as the transcriptional template for the production of viral RNAs that encode viral structural and non-structural proteins. Reverse transcription of the viral pregenomic RNA and second-strand DNA synthesis occur in the cytoplasm within viral capsids formed by the HBV core protein. Because lamivudine, a nucleoside analogue, inhibits reverse transcription of the pregenomic RNA, it directly suppresses the production of HBV virion. Thus, serum HBV DNA levels decrease rapidly after the initiation of lamivudine administration. On the other hand, the production of viral proteins is not suppressed by lamivudine because the production process does not include reverse transcription. Furthermore, it has been reported that the amount of cccDNA, which serves as a template for mRNA, decreases quite slowly after starting the administration of nucleoside analogues (24–26). Thus, it is reasonable that serum HBVcrAg levels decrease much more slowly than

HBV DNA levels after the initiation of lamivudine therapy.

Significant markers that can predict the presence or absence of lamivudine resistance are clinically valuable because the emergence of this resistance and the subsequent recurrence of hepatitis are fundamental problems in lamivudine therapy. Serum markers that reflect the activity of HBV replication have been reported to be associated with the occurrence of lamivudine resistance (11, 12, 27, 28). However, neither the pretreatment existence of HBe antigen nor pretreatment levels of HBV DNA or HBVcrAg were found to be significant markers in the present study. These results may reflect a weak association between the pretreatment activity of HBV replication and the occurrence of lamivudine resistance (13, 29). Changes in HBV DNA and HBVcrAg levels after starting lamivudine administration clearly differed between patients with and without lamivudine resistance. Thus, HBV DNA and HBVcrAg levels at 6 months after starting lamivudine administration were analyzed to determine whether these levels might serve as predictive markers; both were found to be significantly lower in patients without lamivudine resistance at the tested point in time. Furthermore, patients who showed higher levels of HBV DNA and HBVcrAg at 6 months after the initiation of treatment were significantly more likely to develop lamivudine resistance than those who showed lower levels.

We believe that the measurement of HBV DNA levels is useful to identify patients who are at high risk for lamivudine resistance because as many as 70% of patients who were positive for HBV DNA at 6 months after starting lamivudine

Prediction of lamivudine resistance

administration developed lamivudine resistance within 2 years. However, a negative result of HBV DNA at 6 months does not necessarily guarantee the absence of lamivudine resistance because nearly 30% of such patients developed resistance within 2 years. On the other hand, HBVcrAg levels of less than 4.7 log U/ml at 6 months are a useful indicator of patients who are unlikely to develop lamivudine resistance, because no such patients developed resistance during the follow-up period in the present study. Lower serum HBVcrAg levels may reflect lower levels of cccDNA in hepatocytes because the mRNAs of HBVcrAg are transcribed from the cccDNA (18, 22, 23). This possibility may explain our finding that patients whose HBVcrAg levels decreased sufficiently were unlikely to develop lamivudine resistance, because cccDNA provides the templates for viral and pregenomic messenger RNA (18, 22, 23), which may be a source of lamivudine-resistant strains.

In conclusion, our results suggest that measurement not only of HBV DNA but also of HBVcrAg is useful for predicting the occurrence of lamivudine resistance. HBV DNA measurement is valuable for identifying patients who are at high risk of developing this resistance and HBcrAg measurement is valuable for identifying those who are at low risk.

Acknowledgements

This research was supported in part by a research grant on hepatitis from the Ministry of Health, Labour and Welfare of Japan.

References

1. DOONG S L, TSAI C H, SCHINAZI R F, LIOTTA D C, CHENG Y C. Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. *Proc Natl Acad Sci USA* 1991; 88: 8495-9.
2. BENHAMOU Y, DOHIN E, LUNEL-FABIANI F, POYNARD T, HURAUX J M, KATLAMA C, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. *Lancet* 1995; 345: 396-7.
3. DIENSTAG J L, GOLDIN R D, HEATHCOTE E J, HANN H W, WOESSNER M, STEPHENSON S L, et al. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003; 124: 105-17.
4. DIENSTAG J L, PERRILLO R P, SCHIFF E R, BARTHOLOMEW M, VICARY C, RUBIN M. A preliminary trial of lamivudine for chronic hepatitis B infection. *N Engl J Med* 1995; 333: 1657-61.
5. LAI C L, CHIEN R N, LEUNG N W, CHANG T T, GUAN R, TAI D I, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998; 339: 61-8.
6. LIAW Y F, SUNG J J, CHOW W C, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; 351: 1521-31.
7. MATSUMOTO A, TANAKA E, ROKUHARA A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2,795 patients. *Hepatology* 2005; 42: 173-84.
8. LING R, MUTIMER D, AHMED M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. *Hepatology* 1996; 24: 711-3.
9. LOK A S, LAI C L, LEUNG N, YAO G B, CUI Z Y, SCHIFF E R, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003; 125: 1714-22.
10. TIPPLES G A, MA M M, FISCHER K P, BAIN V G, KNETEMAN N M, TYRRELL D L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. *Hepatology* 1996; 24: 714-7.
11. LIAW Y F, CHIEN R N, YEH C T, TSAI S L, CHU C M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. *Hepatology* 1999; 30: 567-72.
12. SUZUKI F, TSUBOTA A, ARASE Y, SUZUKI Y S, AKUTA N, HOSAKA T, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. *Intervirology* 2003; 46: 182-9.
13. ZOLLNER B, SCHAFFER P, FEUCHT H H, SCHROTER M, PETERSEN J, LAUFS R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. *J Med Virol* 2001; 65: 659-63.
14. KIMURA T, ROKUHARA A, SAKAMOTO Y, YAGI S, TANAKA E, KLYOSAWA K, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol* 2002; 40: 439-45.
15. ROKUHARA A, TANAKA E, MATSUMOTO A, KIMURA T, YAMAURA T, ORII K, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. *J Viral Hepatol* 2003; 10: 324-30.
16. BRUSS V, GERLICH W H. Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein. *Virology* 1988; 163: 268-75.
17. GARCIA P D, OU J H, RUTTER W J, WALTER P. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. *J Cell Biol* 1988; 106: 1093-104.
18. LEE W M. Hepatitis B virus infection. *N Engl J Med* 1997; 337: 1733-45.
19. MIZOKAMI M, NAKANO T, ORITO E, TANAKA Y, SAKUGAWA H, MUKAIDE M, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. *FEBS Lett* 1999; 450: 66-71.
20. KOBAYASHI S, SHIMADA K, SUZUKI H, TANIKAWA K, SATA M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). *Hepatology* 2000; 31: 31-42.
21. MASON W S, HALPERN M S, ENGLAND J M, SEAL G, EGAN J, COATES L, et al. Experimental transmission of duck hepatitis B virus. *Virology* 1983; 131: 375-84.
22. SUMMERS J, SMITH P M, HORWICH A L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. *J Virol* 1990; 64: 2819-24.
23. TUTTLEMAN J S, POURCEL C, SUMMERS J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. *Cell* 1986; 47: 451-60.

Tanaka et al.

24. MORALEDA G, SAPUTELLI J, ALDRICH C E, AVERETT D, CONDREAY L, MASON W S. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. *J Virol* 1997; 71: 9392-9.
25. WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, WORS-THORN K, PETERSEN J, LAU G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. *Gastroenterology* 2004; 126: 1750-8.
26. ZHU Y, YAMAMOTO T, CULLEN J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. *J Virol* 2001; 75: 311-22.
27. LAU D T, KHOKHAR M F, DOO E, GHANY M G, HERION D, PARK Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. *Hepatology* 2000; 32: 828-34.
28. YUEN M F, SABLON E, HUI C K, YUAN H J, DE-CRAEMER H, LAI C L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. *Hepatology* 2001; 34: 785-91.
29. MIHM U, SARRAZIN C, HERRMANN E, TEUBER G, VON WAGNER M, KRONEA BERGER B, et al. Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B. *Z Gastroenterol* 2003; 41: 249-54.

Hepatitis C Virus Core Protein Modulates Fatty Acid Metabolism and Thereby Causes Lipid Accumulation in the Liver

ATSUSHI YAMAGUCHI, MD,* SUSUMU TAZUMA, MD, PhD,† TOMOJI NISHIOKA, MD, PhD,*
WAKA OHISHI, MD, PhD,* HIDEYUKI HYOGO, MD, PhD,† SHUICHI NOMURA, MD, PhD,†
and KAZUAKI CHAYAMA, MD, PhD*

We studied the roles of hepatitis C virus (HCV) core protein in hepatic steatosis and changes in hepatic lipid metabolism. HCV core protein expression plasmid was transfected in HepG2. Triacylglyceride (TG) and mRNA level associated with lipid metabolism were measured. Male C57BL/6 mice were infected with HCV core recombinant adenovirus and used for lipids and mRNA studies. In HCV core protein-expressing cells, peroxisome proliferator-activated receptor (PPAR) α , multidrug resistance protein (MDR) 3, and microsomal triglyceride transfer protein (MTP) were down-regulated 48 hr after transfection. In HCV core protein-expressing mice, hepatic TG content and hepatic thio-barbituric acid-reactive substances increased. PPAR α , MDR2, acyl-CoA oxidase (AOX), and carnitine palmitoyl transferase-1 (CPT-1) were down-regulated. HCV core protein down-regulated lipid metabolism-associated gene expression, Mdr2, CPT, and AOX, accompanied by down-regulation of PPAR α . These findings may contribute to the understanding of HCV-related steatosis, induction of reactive oxygen species, and carcinogenesis.

KEY WORDS: HCV core protein; steatosis; nuclear receptor; ABC transporter.

Chronic hepatitis C virus (HCV) infection results in necroinflammatory liver disease that is characterized by the insidious progression of hepatic fibrosis and the loss of functioning hepatocytes (1–3). Little is known about the molecular mechanisms underlying liver injury due to infection with this virus, but a cell-mediated immune response associated with prominent lymphocytic infiltration of hepatic tissues is thought to play a major role (4, 5). In addition, various observations have suggested that nonimmune mechanisms may also play an important role. These

findings include the frequent presence of hepatic steatosis in patients with chronic hepatitis C, an abnormality that is not often observed in other inflammatory conditions such as autoimmune hepatitis and chronic hepatitis B (6–9). Also, a considerable number of *in vitro* studies have suggested that expression of various HCV proteins may lead to alterations of lipid metabolism and transport, cell cycle dysregulation, increased or decreased susceptibility to apoptosis, and cellular transformation (10–17). In particular, HCV core protein has been suggested to contribute to hepatic steatosis (18–20), induction of reactive oxygen species (ROS) (19–21), and hepatic carcinogenesis (22).

Regarding HCV core protein-induced steatosis, the following findings have been reported: (a) HCV core protein interacts with apoA2, a major component of high-density lipoprotein (10, 23), (b) HCV core protein interferes with the assembly of very low-density lipoprotein (VLDL) by reducing the level of microsomal triglyceride transfer

Manuscript received October 7, 2004; accepted December 2, 2004.

From the Departments of *Medicine and Molecular Science and †General Medicine and Clinical Pharmacotherapy, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.

Address for reprint requests: Susumu Tazuma MD, PhD, Department of General Medicine and Clinical Pharmacotherapy, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan; stazuma@hiroshima-u.ac.jp.




Fig 1. Constructs of recombinant adenoviruses and plasmids employed in this study. See Materials and Methods. ATG, start codon; G poly(A), rabbit β -globin poly(A); CAG promoter; cytomegalovirus enhancer, chicken β -actin promoter, and rabbit β -globin poly(A); Ad5, adenovirus type 5 genome lacking E1A, E1B, and E3.

protein (24), and (c) HCV core protein causes steatosis due to mitochondrial toxicity and production of ROS (19, 20). However, the details of the interaction between HCV and lipid metabolism remain unclear. Hepatocytes represent the crossroads of various metabolic pathways, so HCV may interfere with lipid metabolism via one or several pathways. To investigate the role of HCV core protein in steatosis and the accompanying changes in hepatic lipid metabolism, we focused on fatty acid metabolism-associated proteins, including those involved in fatty acid oxidation and lipid transport into blood and bile, as well as nuclear receptors.

MATERIALS AND METHODS

Plasmid and Recombinant Adenovirus. The complementary DNA clone of the full-length HCV core protein (amino acids [aa] 1–191) was derived from the serum of a patient with HCV 1b by reverse transcription and nested polymerase chain reaction. First-strand primers were 5'-CTGCTAGCCGAGTAGTGTTG-3' and 5'-CATTGAGGACCACCAGGTTCT-3', while second-strand primers were 5'-CGGGAATTCTCGTAGACCGTGCACCATGAGC-3' and 5'-GTTGGGATCCTCCTAAGCGGAAGCTGGGAT-3'. The gene was inserted into pBluescript (Stratagene,

La Jolla, CA, USA) and cloned. Then it was made to correspond with HCV 132996 (GenBank) using a QuikChange Site-Directed Mutagenesis kit (Stratagene). The HCV core protein expression plasmid (pCAG-HCVcore), a control plasmid (MOK), and a β -galactosidase expression plasmid (pCAG-LacZ) were prepared using an adenovirus expression vector kit (Takara Biotechnology, Tokyo) (25, 26). The HCV core gene was inserted into the *Swa*I site in cosmid vector pAxCawt, which is a 44,741-kilobase cosmid containing a 31-kilobase adenovirus type 5 genome lacking the E1A, E1B, and E3 genes, but including the cytomegalovirus enhancer, chicken β -actin promoter, and rabbit β -globin poly(A) signal (pAxCaiHCVcore). The cosmid vector pAxCaiLacZ, with the β -galactosidase gene inserted into pAxCawt, was included in the adenovirus expression vector kit. These three vectors (pAxCawt, pAxCaiHCVcore, and pAxCaiLacZ) were digested at the *Sal*I site and ligated, yielding the pCAG-MOK, pCAG-HCVcore, and pCAG-LacZ expression plasmids for cell transfection experiments. The cosmid pAxCaiHCVcore or pAxCaiLacZ was cotransfected into 293 cells with adenovirus DNA by calcium phosphate precipitation. Incorporation of the expression cassette was confirmed by digestion with *Cl*aI. Recombinant adenovirus (AdexCAHCVcore or AdexCALacZ) was propagated in 293 cells and the viral titer was determined as the 50% tissue culture infectious dose using 293 cells. These viruses were used for animal experiments (Figure 1).

Cell Culture. HepG2 cells were seeded into 56-cm² tissue culture dishes in Dulbecco's modified Eagle's medium (DMEM)

(Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO, USA) and an antibiotic/antimycotic mixture (100 U/ml each) (Gibco) and were cultured in a humidified incubator (5% CO₂) at 37°C. The medium was replaced with fresh medium every 3–4 days. Prior to each experiment, the cells were seeded into 6- or 12-well plates and allowed to attach for at least 24 hr (6-well for triglyceride [TG] assay and 12-well for RNA extraction).

Transfection. Using SuperFect Transfection Reagent (Qiagen, Tokyo), cells were transfected with 4 or 3 µg of pCAG-HCVcore or pCAG-MOK (4 µg for 6-well plates and 3 µg for 12-well plates) and were cultured in DMEM with 10% FBS. After 24 or 48 hr, the cells were harvested for analysis. The efficiency of transfection was investigated using pCAG-LacZ. Cells were washed with phosphate-buffered saline (PBS) and fixed with 2% formaldehyde and 0.2% glutaraldehyde in PBS. Then the cells were stained with X-gal using a β-Gal Staining Set (Roche, Tokyo).

Animals. Adult male C57BL/6 mice (Charles River Laboratories, Yokohama, Japan), which were over 8 weeks old and weighed 21–24 g, were used in this study. All animals were housed in an environmentally controlled facility with a 12-hr lighting time (lights on from 0700 until 1900 hr). They were given free access to standard chow and water. Experiments (intravenous injection and sacrifice) were performed from 0900 to 21 hr. The animals received humane care according to the institutional guidelines for handling experimental animals.

HCV Core Protein Expression in Mice. The animals received an intravenous injection of 1 × 10⁹ pfu (plaque-forming units) of AdexCAHCVcore or AdexCALacZ and were sacrificed 3 days later. Mice were anesthetized with pentobarbital (100 mg/kg intraperitoneally). Blood was collected by cardiac puncture with a heparinized syringe, after which the liver was rapidly removed, weighed, and perfused with ice-cold PBS (pH 7.4). Part of the liver was fixed in 10% neutral buffered formalin and embedded in paraffin for histologic analysis. Another part was stored in RNA later reagent (Qiagen, Tokyo) at 4°C for extraction of RNA, and the remaining liver tissue was snap-frozen in liquid nitrogen and stored at –80°C until required. Plasma was immediately separated by centrifugation (10,000 rpm at 4°C) and stored at –20°C.

Liver Histology and Serum ALT Level. Sections of liver tissue (4 µm thick) were stained with hematoxylin and eosin for analysis. The serum alanine aminotransferase (ALT) level was measured using an automated technique by SRL Co. (Hiroshima, Japan).

HCV Core Protein Expression in Cells. Proteins were extracted from cells using PRO-PREP protein extraction solution (containing 1.0 mM PMSF, 1.0 mM EDTA, 1 µM pepstatin, 1 µM leupeptin, and 1 µM aprotinin) (Intron Biotechnology, Kyungki-Do, Korea). HCV core antigen levels were measured in cells using an HCV core antigen enzyme-linked immunosorbent assay (ELISA) (Ortho-Clinical Diagnostics K.K., Tokyo).

HCV Core Protein Expression in Mice. We confirmed HCV core protein expression in liver tissue by Western blot analysis. Proteins were extracted using PRO-PREP protein extraction solution. Then 50 µg of protein was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Millipore, Bedford, MA, USA) using a tank blotting system according to the manufacturer's instructions (Bio-Rad Laboratories). After transfer, the membrane was blocked for 2 hr at room temperature with 5%

powdered skim milk dissolved in Tris-buffered saline containing 0.05% between 20 and then incubated overnight at 4°C with a monoclonal mouse antibody to HCV core protein (kindly provided by Ortho-Clinical Diagnostics K.K.). Immune complexes were detected using alkaline phosphatase-conjugated anti-mouse IgG (Cosmo Bio, Tokyo) according to the manufacturer's instructions (Bio-Rad Laboratories). Detection of HCV core protein was performed by comparison with the following standards: myosin (200 kDa), β-galactosidase (116 kDa), bovine serum albumin (66 kDa), carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21.5 kDa), lysozyme (14.4 kDa), and aprotinin (6.5 kDa).

Measurement of Triglyceride Content. After the medium was removed, the cells were washed three times with PBS and resuspended in 200 µl of PBS. Then lipids were extracted from 100 µl of PBS by the method of Bligh and Dyer (27) and resuspended in 100 µL of 10% Triton X. The cellular content of TG was measured using enzyme reagents and standards from Wako (Osaka, Japan). The remainder of the PBS suspension was used for the protein assay. In mice experiments, livers were homogenized in PBS and 100 µl of the homogenate was used for extraction of lipids. Total protein was measured with protein assay reagents from Bio-Rad (Richmond, CA, USA).

Hepatic Level of Thiobarbituric Acid-Reactive Substances (TBARS). The hepatic level of TBARS was measured using an OXI-TEK TBARS Assay Kit (Zeptometrix Corporation, New York, USA). Briefly, 100 mg of liver tissue was homogenized in 10 vol of normal saline. Then 100 µl of SDS and 2.5 ml of TBA/buffer reagent were added to 100 µl of this homogenate or the malondialdehyde standard. Samples were incubated at 95°C for 60 min, cooled in an ice bath for 10 min, and centrifuged at 3000 rpm for 15 min, after which the supernatant was analyzed by spectrophotometry (532 nm).

Extraction of RNA and RT-PCR. The medium was removed and the cells were washed twice with PBS. After centrifugation, total RNA was isolated using an RNeasy Mini Kit (Qiagen, Tokyo). From mouse, 20 mg of liver tissue was used for RNA extraction. Then 2 µg of total RNA was employed for reverse transcription using random hexamers (final concentration: 2.5 µM) and murine leukemia virus reverse transcriptase (final concentration: 2.5 U/µl) (Roche, Tokyo). Specific primer sets were synthesized for performance of the PCR (Table 1) and were used for assessment of liver-predominant mitochondrial carnitine palmitoyl transferase-1 (CPT1A in humans and CPT1 in mice; the rate-limiting enzyme of mitochondrial β-oxidation), acyl-CoA oxidase (ACO1 in humans and AOX in mice; the rate-limiting enzyme of peroxisomal β-oxidation), cytochrome P-450 4A11 (CYP4A11; involved in microsomal ω-oxidation), multidrug resistance protein 3 (MDR3 in humans and Mdr2 in mice; an ABC transporter and phospholipid flippase), microsomal TG transfer protein (MTP; a vital protein for TG incorporation into VLDL), and two nuclear receptors (peroxisome proliferator-activated receptor α [PPARα] and peroxisome proliferator-activated receptor γ [PPARγ]). Roles of these genes are summarized in Table 2. Amplification involved 30 cycles of denaturation at 95°C for 60 sec, annealing at each specified temperature (Table 1) for 30 sec, and extension at 72°C for 60 sec. The reaction products were analyzed on a 2% agarose gel and were visualized by ethidium bromide staining. The PCR products were excised from the gel, purified using a gel purification kit (Qiagen), and quantified by spectrophotometry. Dilutions

TABLE 1. PRIMER SETS IN THE EXPERIMENTS

	Forward	Reverse	Annealing temp. (°C)
Human			
GAPDH	GAACGGGAAGCTCACTGGCATGGC	TGAGGTCCACCCTGTTGCTG	65
PPAR α	GGAAAGCCCACTTGCCCCCT	AGTCACCGAGGAGGGGCTCGA	63
PPAR γ	CATTCTGGCCACCAACTTTGG	TGGAGATGCAGGCTCCACTTTG	63
MDR3 (ABCB4)	GATGAAAAGGCTGCCACTAG	TTGCACTTCTGCTGCTTAC	62
MTP	GGCTAGCCTATTTTCAGACACA	GATGAGCCTGGTAGGTCCT	60
CPT1A	AGACGGTGGAACAGAGGCTGAAG	TGAGACCAAACAAAGTGATGATGTCAG	67
ACO1	GGGCATGGCTATTCTCATTGC	CGAACAAAGGTCAACAGAAGTTAGGTTC	60
CYP4A11	GTGGCCCAACCCAGAGGT	TCCCAATGCAGTTCCTTGATC	55
Mouse			
GAPDH	AGAACATCCCTGCATCC	TGTGTCATTGAGAGCAATGCC	56
PPAR α	TGCAGAGCAACCATCCAG	TAATGGCGAATTATAAAC	50
PPAR γ	GGTGAAACTCTGGGAGATTCT	CAACCAATGGGTGAGCTCTT	59
Mdr2 (Abcb4)	TATCCGCTATGGCCGTGGGAA	ATCGGTGAGCTATCACAATGG	56
MTP	TGAGCGGTATACAAGCTCAC	CTGGAAGATGCTCTTCTCGC	60
LCPT	CGCACGGAAGGAAAATGG	TGTGCCCAATATTCTCTGG	52
AOX	CTTGTTCGCGCAAGTGAGG	CAGGATCCGACTGTTTACC	56

ranging from 3×10^{-5} to 3×10^2 pg were prepared in water and used as the standards.

Quantitative PCR. Quantitative PCR was performed using the Light-Cycler Fast-Start DNA Master SYBR Green system (Roche Molecular Biochemicals, Tokyo). PCR was carried out in a final reaction volume of 20 μ l using 1 μ l of each primer at 10 μ M (final concentration: 0.5 μ M), 1.6 μ l of 25 mM MgCl₂ (final concentration: 3 mM), 2 μ l of the enzyme mix supplied, 12.4 μ l of H₂O, and 2 μ l of the template. The enzyme mix contained the reaction buffer, Fast-Start Taq DNA polymerase, and DNA double strand-specific SYBR Green I dye for detection of PCR products. PCR was performed in a Light-Cycler (Roche) with preincubation for 10 min at 95°C followed by 40 cycles of denaturation for 15 sec at 95°C, annealing for 5 sec at each specified temperature (see Table 1), and extension for 25 sec at 72°C, with fluorescent detection at the end of extension. Next, the PCR products were subjected to melting curve analysis to exclude the amplification of primer dimmers or other nonspecific products. If primer dimmers and nonspecific bands were detected, fluorescence detection was repeated after extension at each specified temperature for 1 sec. Analysis was carried

out with Light-Cycler 3.5 software (Roche). Quantification was done using the "point fitting" mode and baseline adjustment. The standard curve for each gene was created using five different dilutions. The plot of the number of PCR cycles versus log concentration was considered reliable when the error was <0.2.

Statistical Analysis. Results are expressed as the mean \pm SE. Statistical analysis was performed using Student's *t*-test, and *P* < 0.05 was defined as indicating significance.

RESULTS

HCV Core Protein Expression in HepG2 Cells. The transfection efficiency of pCAG-LacZ was about 20%. HCV core protein expression by the cells was confirmed using the HCV core antigen ELISA. No HCV core antigen was detected in mock-transfected and nontransfected cells. The level of HCV core protein expression showed no difference between 24 and 48 hr after transfection (24 hr,

TABLE 2. ROLES OF ANALYZED GENES IN FATTY ACID METABOLISM

MDR3	Multidrug resistance protein 3 An ABC transporter and phospholipid flippase <i>Role: Phospholipid secretion into bile</i>
MTP	Microsomal triglyceride transfer protein A vital protein for TG incorporation into VLDL <i>Role: triglyceride secretion into blood</i>
CPT1A	Liver-predominant mitochondrial carnitine palmitoyl transferase-1 The rate-limiting enzyme of mitochondrial β -oxidation <i>Role: Fatty acid β-oxidation in the liver</i>
ACO1	Acyl-CoA oxidase The rate-limiting enzyme of peroxisomal β -oxidation <i>Role: Fatty acid β-oxidation in the liver</i>
PPAR α	Peroxisome proliferator-activated receptor α A nuclear receptor <i>Role: A nuclear receptor controlling lipid metabolism-associated genes</i>
PPAR γ	Peroxisome proliferator-activated receptor γ A nuclear receptor <i>Role: A nuclear receptor controlling lipid metabolism-associated genes</i>




Fig 2. Effect of HCV core protein expression on cellular triglyceride (TG) content. Four micrograms of pCAG-MOK (control) or pCAG-HCVcore was transfected into HepG2 cells cultured in six-well plates by the lipofection method. At 24 or 48 hr after transfection, cells were collected for protein assay and lipid extraction. TG content was measured and expressed as the ratio to the protein content. Data are shown as values relative to those for nontransfected HepG2 cells. Each data point represents the mean \pm SD of six individual experiments. $P = NS$ compared with pCAG-MOK (Student's *t*-test).

1.31 \pm 0.20 nmol/mg protein; 48 hr, 1.25 \pm 0.16 nmol/mg protein).

TG Content of HepG2 Cells. The cellular TG content at 24 hr after transfection showed no difference between HCV core transfectants (CORE) and mock transfectants (MOK) as control (CORE, 1.16 \pm 0.19; MOK, 1.10 \pm 0.13; $P = 0.57$). At 48 hr after transfection, the TG content also showed no difference between the groups (CORE, 0.88 \pm 0.16; MOK, 0.95 \pm 0.18; $P = 0.55$). Data are expressed as the ratio to nontransfected cells (Figure 2).

Expression of Target Genes by HepG2 Cells. At 24 hr after transfection, HCV CORE showed increased expression of mRNA for PPAR γ (CORE, 2.39 \pm 0.26; MOK, 1.98 \pm 0.28; $P = 0.025$), MDR3 (CORE, 1.30 \pm 0.21; MOK, 1.02 \pm 0.20; $P = 0.030$), MTP (CORE, 0.37 \pm 0.04; MOK, 0.26 \pm 0.05; $P < 0.01$), and ACO1 (CORE, 1.11 \pm 0.14; MOK, 0.76 \pm 0.08; $P < 0.01$) compared to MOK, while CPT (CORE, 1.18 \pm 0.16; MOK, 0.94 \pm 0.28; $P = 0.102$) and PPAR α (CORE, 0.84 \pm 0.14; MOK, 0.69 \pm 0.10; $P = 0.055$) expression was normal (Figure 3). At 48 hr after transfection, HCV CORE showed lower expression of mRNA for PPAR α (CORE, 0.89 \pm 0.02; MOK, 0.96 \pm 0.08;




Fig 3. Effect of HCV core protein expression on mRNA levels at 24 hr after transfection. Three micrograms of pCAG-MOK (control) or pCAG-HCVcore was transfected into HepG2 cells cultured in 12-well plates by the lipofection method. At 24 hr after transfection, cells were collected for extraction of RNA. Complementary DNA was synthesized from 2 μ g of RNA and used for quantified PCR with the Light-Cycler Fast-Start DNA Master SYBR Green system. GAPDH level was measured as the internal control, and the ratio to GAPDH was calculated for each sample. Data are shown as values relative to those for nontransfected HepG2 cells. Each data point represents the mean \pm SD of 6 individual experiments. * $P < 0.05$ compared with pCAG-MOK (Student's *t*-test).




Fig 4. Effect of HCV core protein on mRNA expression at 48 hr after transfection. Three micrograms of pCAG-MOK (control) or pCAG-HCVcore was transfected into HepG2 cells cultured in 12-well plates by the lipofection method. At 48 hr after transfection, cells were collected and used for RNA extraction. Complementary DNA was synthesized from 2 μ g of RNA and used for quantified PCR with the Light-Cycler Fast-Start DNA Master SYBR Green system. GAPDH was measured as an internal control, and the ratio to GAPDH was calculated for each sample. Data are shown as values relative to those for nontransfected HepG2 cells. Each data point represents the mean \pm SD of 6 individual experiments. * $P < 0.05$ compared with pCAG-MOK (Student's *t*-test).

$P = 0.048$), MDR3 (CORE, 0.75 ± 0.06 ; MOK, 0.86 ± 0.08 ; $P = 0.031$), and MTP (CORE, 0.69 ± 0.08 ; MOK, 0.81 ± 0.07 ; $P = 0.016$) compared with MOK, while ACO1 returned to the control level (CORE, 0.91 ± 0.18 ; MOK, 0.88 ± 0.09 ; $P = 0.70$) and the CPT level was normal (CORE, 0.94 ± 0.13 ; MOK, 0.86 ± 0.10 ; $P = 0.27$). Data are expressed as the ratio to nontransfected cells (Figure 4). Experiments were repeated three times and similar results were obtained, with statistical significance. CYP4A11 was not detected by RT-PCR, so we could not make a standard for the Light-Cycler.

HCV Core Protein Expression in Mice. HCV core protein-expressing mice looked healthy and their body weight (BW) and liver weight remained within the normal range (BW [g]: PBS, 22.5 ± 0.816 ; AdexCAHCVcore (CORE), 21.7 ± 0.84 ; AdexCALacZ (LacZ), as control, 21.5 ± 0.71). Similar mild elevation of ALT and mild hepatic lymphocyte infiltration were observed in both groups of adenovirus-infected mice, showing no differences between Core and LacZ (GPT [IU/ml]: PBS, 65 ± 17.8 ; CORE, 170 ± 59.4 ; LacZ, 142.5 ± 82.2). Lipid drops were not observed in either group (data not shown). Western blot analysis revealed the HCV core protein of about 19–20 kDa (Figure 5). In preliminary experiments, animals receiving an intravenous injection of 1×10^9 pfu developed severe hepatitis after 7 days, while animals re-

ceiving 1×10^8 pfu showed a mild elevation of ALT, but their HCV core protein expression (based on quantification of mRNA and HCV core antigen) was significantly lower at 7 days after injection. Thus, we selected injection of 1×10^9 pfu and sacrifice at 3 days for the study protocol.




Fig 5. HCV core protein expression in mice. AdexCALacZ (control recombinant adenovirus) or AdexCAHCVcore was used to infect male C57BL/6 mice (8–10 weeks old) by intravenous administration (1×10^9 pfu). Three days after infection, livers were collected for protein assay. Using 50 μ g of protein, HCV core protein expression was confirmed by Western blotting with a mouse monoclonal antibody for HCV core protein (19–20 kDa).




Fig 6. Effect of HCV core protein expression on the hepatic triglyceride content in mice. AdexCALacZ (control adenovirus) or AdexCAHCVcore was used to infect male C57BL/6 mice (8–10 weeks old) by intravenous administration (1×10^9 pfu). At 3 days after infection, the livers were collected and 100 μ l of liver homogenate was used for lipid extraction and for the protein assay. The TG content was measured and expressed as the ratio to the protein content. Data are shown as values relative to those for noninfected mice. Each data point represents the mean \pm SD of four individual mice. * $P < 0.05$ compared with AdexCALacZ (control adenovirus) by Student's *t*-test.

Hepatic TG Level in Mice. Animals injected with AdexCAHCVcore showed a 1.45-fold increase in hepatic TG content compared to animals injected with AdexCALacZ (CORE, 1.60 ± 0.33 ; LacZ, 1.10 ± 0.21 ; $P = 0.044$; $N = 4$). Data are expressed as the ratio to noninfected mice (Figure 6).

Expression of Target Genes in Mice. In the livers of HCV core protein-expressing mice, PPAR α (CORE, 0.59 ± 0.11 ; LacZ, 1.33 ± 0.21 ; $P < 0.01$), PPAR γ (CORE, 1.05 ± 0.10 ; LacZ, 2.43 ± 0.69 ; $P < 0.01$), Mdr2 (CORE, 0.85 ± 0.08 ; LacZ, 1.12 ± 0.12 ; $P = 0.011$), AOX (CORE, 0.235 ± 0.08 ; LacZ, 0.401 ± 0.07 ; $P = 0.02$), and CPT (CORE, 1.14 ± 0.14 ; LacZ, 2.34 ± 0.51 ; $P < 0.01$) were all down-regulated, while the level of MTP mRNA was unchanged (CORE, 1.37 ± 0.08 ; LacZ, 1.24 ± 0.17 ; $P = 0.22$; $N = 4$). Data are expressed as the ratio to noninfected mice (Figure 7).

Hepatic TBARS Level. In the livers of HCV core protein-expressing mice, the TBARS level was increased compared with that in the control group (CORE, 0.84 ± 0.08 ; LacZ, 0.41 ± 0.01 ; $P < 0.01$; $N = 4$) (Figure 8).




Fig 7. Effect of HCV core protein expression on mRNA levels in mice. AdexCALacZ (control adenovirus) or AdexCAHCVcore was used to infect male C57BL/6 mice (8–10 weeks old) by intravenous administration (1×10^9 pfu). At 3 days after infection, livers were collected for RNA extraction. Complementary DNA was synthesized from 2 μ g of RNA and used for quantified PCR with the Light-Cycler Fast-Start DNA Master SYBR Green system. GAPDH was measured as an internal control, and the ratio to GAPDH was calculated for each sample. Data are shown as relative values to those for noninfected mice. Each data point represents the mean \pm SD of four individual mice. * $P < 0.05$ and ** $P < 0.01$ compared with AdexCALacZ (control adenovirus) by Student's *t*-test.




Fig 8. Effect of HCV core protein expression on TBARS in the mouse liver. AdexCALacZ (control adenovirus) or AdexCAHCVcore was used to infect male C57BL/6 mice (8–10 weeks old) by intravenous administration (1×10^9 pfu). At 3 days after infection, livers were homogenized in 10 vol of normal saline. TBARS and total protein (TP) levels were measured as described under Materials and Methods. Data are expressed as the ratio to the TP level. Each data point represents the mean \pm SD of four individual mice. * $P < 0.01$ compared with AdexCALacZ (control adenovirus) by Student's *t*-test.

DISCUSSION

HCV core protein was recently reported to cause hepatic steatosis and induction of reactive oxygen species (ROS) in an HCV core protein transgenic mouse model (18–20). In the transgenic mouse model, it was also shown that a decrease in MTP activity contributes to HCV core protein-related steatosis, while β -oxidation is unchanged (24), but the mechanism involved is still unclear. This study was the first investigation of the effect of HCV core protein on the expression of fatty acid metabolism-associated molecules in the acute expression mice model.

Hepatic accumulation of TG is principally driven by the following factors: (a) fatty acid overload (28, 29), (b) inhibition of fatty acid β -oxidation (28, 29), (c) decreased secretion of TG-rich very low density lipoprotein (VLDL) (28, 29), (d) increased de novo fatty acid synthesis, (e) decreased transformation to phospholipids, and (f) a combination of these mechanisms.

In the present study, we initially tested the effect of HCV core protein on a human cell line (HepG2). At 24 hr after transfection, the cellular TG level was unchanged, but the expression of several genes that are thought to promote fatty acid consumption (MTP, ACO1, and MDR3) was up-regulated. At 48 hr after transfection, there was either normal gene expression (ACO1) or a decrease in expression (PPAR α , MDR3, and MTP). At 48 hr after transfection, the level of HCV core antigen was still the same as at 24 hr, so it seems possible that HCV core protein may

act to down-regulate these genes over a longer period. To further evaluate the effects of HCV core protein, we performed in vivo experiments using transient expression of HCV core protein in mice. Although fatty change of the liver was not seen histologically, the hepatic TG level was increased by transient HCV core protein expression. In addition, expression of mRNA for all of the molecules investigated, except MTP, was down-regulated by HCV core protein expression. The mechanism involved is not understood at present, but reduced expression of these genes might contribute to hepatic TG accumulation.

CPT is the rate-limiting enzyme for mitochondrial β -oxidation (30), which is the main pathway of fatty acid consumption and ROS production. There was a recent report (20) that localization of HCV core protein in the mitochondria led to the increased production of ROS, decreased mitochondrial membrane permeability, and impairment of mitochondrial function. It remains unclear whether ROS induces fat accumulation or whether the accumulation of fat causes an increase in ROS, as well as whether decreased expression of CPT-1 is the first response to HCV core protein expression or follows other earlier changes. However, HCV core expression seems to contribute to hepatic accumulation of lipids and an increase in ROS in mice, along with reduced expression of various fatty acid metabolism-associated genes. AOX is vital for peroxisomal β -oxidation (30) and it has been reported that AOX knockout mice develop steatohepatitis, up-regulation of CYP4A gene expression, and increased production of ROS (31). We were unable to evaluate CYP4A11 in the present study, but the association of HCV-related steatosis with microsomal ω -oxidation is interesting. Mdr2 (Abcb4) is a member of the Abcb subfamily of adenosine triphosphate-binding cassette (ABC) transporter proteins. Mdr2 Pgp is exclusively localized to the canalicular membrane and controls the secretion of phospholipids into the bile (32). We thought that impaired biliary phospholipid secretion might have a role in HCV-related steatosis, based on the fact that phospholipid-associated fatty acid secretion into bile (about 25 μ mol per day) is substantial in relation to the hepatic amount of triglyceride-associated fatty acids (about 75 μ mol) (33). We found that the expression of MDR3 and Mdr2 was down-regulated, suggesting that reduced expression of these genes could have a causative role in HCV-related steatosis.

Interestingly, down-regulation of Mdr2, AOX, and CPT in the mice was accompanied by down-regulation of PPAR α . In mice, the other three genes are thought to undergo transcriptional regulation by PPAR α (33, 34), so their expression might be down-regulated secondary to the down-regulation of PPAR α . HCV core protein is mainly

localized in the cytosol, but also exists in the nucleus (35, 36), so it is possible that this protein could influence gene transcription. Tsustumi *et al.* (37) used a luciferase assay to show that transcriptional activation of ACO-1 via PPRE is promoted at 24 hr after HCV core protein expression (23). However, we found down-regulation of target gene expression accompanied by decreased PPAR α expression after 3 days of HCV core protein expression in mice, as well as at 48 hr after transfection of cells. The expression of PPAR α was reported to be under transcriptional regulation by glucocorticoids (38), but the mechanism remains unclear. Accordingly, the mechanism leading to down-regulation of PPAR α after HCV core protein expression is also unclear. The lower expression of PPAR α and the genes it regulates in human hepatocytes than in mouse hepatocytes (39) could be a reason for the lack of an increase in TG and the small decline in gene expression in our cell experiment. Fibrates that bind with PPAR α and increase its activity (although not its expression) might be useful for controlling HCV-related steatosis by increasing the β -oxidation and biliary secretion of fatty acids.

PPAR γ improves insulin resistance and is also reported to improve hepatic fibrosis and nonalcoholic steatohepatitis (40, 41). Because PPAR γ gene expression also showed down-regulation by HCV core protein expression in this study, it may be necessary to examine the role of glucose metabolism, de novo synthesis of fatty acids from glucose, and fatty acid flux through hepatocytes in HCV-related steatosis.

In this study, the increase in TBARS level was found in mice with transient expression of HCV core protein. This suggests that ROS production might be induced by HCV core protein expression, although no mechanistic information for this was provided in this study. It also remains unclear whether intrahepatic fat accumulation enhances ROS production as reflected by an increase in TBARS or, inversely, whether ROS production induces fatty liver change through ROS-associated mitochondrial dysfunction. Certainly, further investigations are needed to clarify this uncertainty, but the fact that HCV core protein expression in mice contributes to the increase in TBARS level may partially characterize the pathogenesis of HCV-related hepatic damage.

In summary, transient expression of HCV core protein in mice down-regulated the expression of various lipid metabolism-associated genes (Mdr2, CPT, and AOX). It also caused down-regulation of PPAR α expression and led to the accumulation of TG and the induction of oxidative stress. These findings may provide some clues to the understanding of HCV-related steatosis and to the induction of ROS production and carcinogenesis by infection with this virus.

REFERENCES

- Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of community-acquired hepatitis C in the United States. *N Engl J Med* 327:1899–1905, 1992
- Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Steevens CE, Hollingworth CG, NHLBI study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. *N Engl J Med* 327:1906–1911, 1992
- Seeff LB: Natural history of hepatitis C. *Hepatology* 26:21S–28S, 1997
- Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. *J Immunol* 149:3339–3344, 1992
- Cerny A, Chisari FV: Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. *Hepatology* 30:595–601, 1999
- Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 33:106–115, 2000
- Scheuer PJ, Davies SE, Dhillon AP: Histopathological aspects of viral hepatitis. *J Viral Hepat* 3:277–283, 1996
- Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsustumi T, Takayama T, Makuuchi M, Matsuura Y, Miyamura T, Kimura S, Koike K: Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. *J Med Virol* 59:141–145, 1999
- Goodman ZD, Ishak KG: Histopathologic findings in chronic hepatitis C virus infection. *Semin Liver Dis* 15:70–81, 1995
- Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. *Proc Natl Acad Sci USA* 94:1200–1205, 1997
- Ray RB, Lagging LM, Meyer K, Ray R: Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. *J Virol* 70:4438–4443, 1996
- Ray RB, Meyer K, Ray R: Suppression of apoptotic cell death by hepatitis C virus core protein. *Virology* 226:176–182, 1996
- Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai MM: Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. *J Virol* 72:3691–3697, 1998
- Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM: Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. *Hepatology* 31:1351–1359, 2000
- Sakamuro D, Furukawa T, Takegami T, Sakamuro D, Furukawa T, Takegami T: Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. *J Virol* 69:3893–3896, 1995
- McLauchlan J, Lemberg MK, Hope G, Martoglio B: Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. *EMBO J* 21:3980–3988, 2002
- Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM: Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* 292:198–210, 2002
- Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis C virus core protein

- induces hepatic steatosis in transgenic mice. *J Gen Virol* 78:1527–1531, 1997
19. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. *Gastroenterology* 122:352–365, 2002
 20. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. *Gastroenterology* 122:366–375, 2002
 21. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res* 61:4365–4370, 2001
 22. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 4:1065–1067, 1998
 23. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, Matsuura Y, Miyamura T, Brechot C, Barba G: Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. *Hepatology* 30:1064–1076, 1999
 24. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, Koike K, Pessayre D, Chapman J, Barba G, Brechot C: Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. *FASEB J* 16:185–194, 2002
 25. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I: Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. *Proc Natl Acad Sci USA* 93:1320–1324, 1996
 26. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakaki T, Sugano S, Saito I: Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. *Nucleic Acids Res* 23:3816–3821, 1995
 27. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. *Can J Med Sci* 37:911–917, 1959
 28. Day CP, James OF: Hepatic steatosis: Innocent bystander or guilty party? *Hepatology* 27:1463–1466, 1988
 29. Fong DG, Nehra V, Lindor KD, Buchman AL: Metabolic and nutritional considerations in nonalcoholic fatty liver. *Hepatology* 32:3–10, 2000
 30. Reddy JK: Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 281:G1333–G1339, 2001 (review)
 31. Fan C, Pan J, Chu R, Lee D, Kluckman KD, Usuda N, Singh I, *et al.*: Hepatocellular and hepatic peroxisomal alternation in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. *J Biol Chem* 271:24698–24710, 1996
 32. Smit JJ, Schinkel AH: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. *Cell* 75:451–462, 1993
 33. Kok T, Wolters H, Bloks V, Havinga R, Jansen P, Ateals B, Kuipers F: Induction of hepatic ABC transporter expression is part of the PPAR α -mediated fasting response in the mouse. *Gastroenterology* 124:160–171, 2002
 34. Duplus E, Forest C: Is there a single mechanism for fatty acid regulation of gene transcription? *Biochem Pharmacol* 64:893–901, 2002 (review)
 35. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mouse. *Nat Med* 4:1065–1067, 1998
 36. Yasui K: The native form and maturation process of hepatitis C virus core protein. *J Virol* 72:6048–6055, 1998
 37. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T: Interaction of hepatitis C virus core protein with retinoid X receptor α modulates its transcriptional activity. *Hepatology* 35:937–946, 2002
 38. Lemberger T, Saladin R, Vazquez M, Assimakopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J: Expression of the peroxisome proliferators-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. *J Biol Chem* 19:1764–1769, 1996
 39. Hsu M, Savas U, Griffin K, Johnson E: Identification of peroxisome proliferators-responsive human genes by elevated expression of peroxisome proliferators-activated receptor α in HepG2 Cells. *J Biol Chem* 276:27950–27958, 2001
 40. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology* 38:1008–1017, 2003
 41. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of community-acquired hepatitis C in the United States. *N Engl J Med* 327:1899–1905, 1992
 42. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Steevens CE, Hollingworth CG, NHLBI study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. *N Engl J Med* 327:1906–1911, 1992
 43. Seeff LB: Natural history of hepatitis C. *Hepatology* 26:21S–28S, 1997
 44. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. *J Immunol* 149:3339–3344, 1992
 45. Cerny A, Chisari FV: Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. *Hepatology* 30:595–601, 1999
 46. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 33:106–115, 2000
 47. Scheuer PJ, Davies SE, Dhillon AP: Histopathological aspects of viral hepatitis. *J Viral Hepat* 3:277–283, 1996
 48. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, Makuuchi M, Matsuura Y, Miyamura T, Kimura S, Koike K: Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. *J Med Virol* 59:141–145, 1999
 49. Goodman ZD, Ishak KG: Histopathologic findings in chronic hepatitis C virus infection. *Semin Liver Dis* 15:70–81, 1995
 50. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. *Proc Natl Acad Sci USA* 94:1200–1205, 1997
 51. Ray RB, Lagging LM, Meyer K, Ray R: Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. *J Virol* 70:4438–4443, 1996
 52. Ray RB, Meyer K, Ray R: Suppression of apoptotic cell death by hepatitis C virus core protein. *Virology* 226:176–182, 1996

HCV CORE PROTEIN MODULATES FATTY ACID METABOLISM

53. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai MM: Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. *J Virol* 72:3691–3697, 1998
54. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM: Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. *Hepatology* 31:1351–1359, 2000
55. Sakamuro D, Furukawa T, Takegami T, Sakamuro D, Furukawa T, Takegami T: Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. *J Virol* 69:3893–3896, 1995
56. McLaughlan J, Lemberg MK, Hope G, Martoglio B: Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. *EMBO J* 21:3980–3988, 2002
57. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM: Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* 292:198–210, 2002
58. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J Gen Virol* 78:1527–1531, 1997
59. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. *Gastroenterology* 122:352–365, 2002
60. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. *Gastroenterology* 122:366–375, 2002
61. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res* 61:4365–4370, 2001
62. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 4:1065–1067, 1998
63. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, Matsuura Y, Miyamura T, Brechot C, Barba G: Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. *Hepatology* 30:1064–1076, 1999
64. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, Koike K, Pessayre D, Chapman J, Barba G, Brechot C: Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. *FASEB J* 16:185–194, 2002
65. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I: Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. *Proc Natl Acad Sci USA* 93:1320–1324, 1996
66. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakaki T, Sugano S, Saito I: Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. *Nucleic Acids Res* 23:3816–3821, 1995
67. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. *Can J Med Sci* 37:911–917, 1959
68. Day CP, James OF: Hepatic steatosis: Innocent bystander or guilty party? *Hepatology* 27:1463–1466, 1988
69. Fong DG, Nehra V, Lindor KD, Buchman AL: Metabolic and nutritional considerations in nonalcoholic fatty liver. *Hepatology* 32:3–10, 2000
70. Reddy JK: Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 281:G1333–G1339, 2001 (review)
71. Fan C, Pan J, Chu R, Lee D, Kluckman KD, Usuda N, Singh I, et al.: Hepatocellular and hepatic peroxisomal alternation in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. *J Biol Chem* 271:24698–24710, 1996
72. Smit JJ, Schinkel AH: Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. *Cell* 75:451–462, 1993
73. Kok T, Wolters H, Bloks V, Havinga R, Jansen P, Ateals B, Kuipers F: Induction of hepatic ABC transporter expression is part of the PPAR α -mediated fasting response in the mouse. *Gastroenterology* 124:160–171, 2002
74. Duplus E, Forest C: Is there a single mechanism for fatty acid regulation of gene transcription? *Biochem Pharmacol* 64:893–901, 2002 (review)
75. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mouse. *Nat Med* 4:1065–1067, 1998
76. Yasui K: The native form and maturation process of hepatitis C virus core protein. *J Virol* 72:6048–6055, 1998
77. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T: Interaction of hepatitis C virus core protein with retinoid X receptor α modulates its transcriptional activity. *Hepatology* 35:937–946, 2002
78. Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J: Expression of the peroxisome proliferators-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. *J Biol Chem* 19:1764–1769, 1996
79. Hsu M, Savas U, Griffin K, Johnson E: Identification of peroxisome proliferators-responsive human genes by elevated expression of peroxisome proliferators-activated receptor α in HepG2 Cells. *J Biol Chem* 276:27950–27958, 2001
80. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology* 38:008–1017, 2003
81. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. *Hepatology* 39:188–196, 2004

Angiotensin II Participates in Hepatic Inflammation and Fibrosis through MCP-1 Expression

KEISHI KANNO, MD,* SUSUMU TAZUMA, MD,† TOMOJI NISHIOKA, MD,* HIDEYUKI HYOGO, MD,†
and KAZUAKI CHAYAMA, MD*

In this study, we assessed the hypothesis that angiotensin (Ang) II could modulate inflammatory cell recruitment into the liver through hepatic expression of monocyte chemoattractant protein (MCP)-1 during liver injury. For in vivo study, Ang II type 1a knockout (AT1a KO) mice and wild-type (WT) mice were treated with CCl₄ for 4 weeks. After CCl₄ treatment, AT1a KO mice showed lower expression of MCP-1 and fewer CD68-positive cells in the liver compared with WT mice. For in vitro study, Ang II was added to LI90 cells. Ang II enhanced MCP-1 mRNA together with RhoA mRNA and also induced secretion of MCP-1 into the culture medium. This change was strongly blocked by Y-27632, a specific Rho-kinase inhibitor. These results suggest that Ang II modulates hepatic inflammation via production of MCP-1 by hepatic stellate cells, and the effect of Ang II on MCP-1 production is, at least partly, mediated by the Rho/Rho-kinase pathway.

KEY WORDS: renin–angiotensin system; monocyte chemoattractant protein-1; hepatic stellate cell; hepatic inflammation; hepatic fibrosis; angiotensin II type 1a knockout mouse; small G protein; Rho/Rho-kinase pathway; carbon tetrachloride.

The renin–angiotensin system (RAS) not only plays an important role in the regulation of systemic hemodynamics, but also functions as a growth factor in various organs, including the vasculature, kidneys, and liver. Activated hepatic stellate cells (HSCs), which are major producers of extracellular matrix after liver injury, express the angiotensin (Ang) II receptor (1), and inhibition of Ang II synthesis or blockade of Ang II signaling reduces experimental hepatic fibrosis (2–4). Our previous study showed that mice lacking the Ang II type 1a receptor (AT1a) were resistant to the development of hepatic fibrosis after exposure to carbon tetrachloride (CCl₄) (5). Moreover, local

hepatic expression of key components of the RAS was up-regulated in an animal model of bile duct ligation (6), and the major cellular source of Ang II in the fibrotic liver was shown to be HSC (7). Overall, these reports support a contribution of the RAS to hepatic fibrogenesis.

Chemokines are low molecular weight secretory proteins that principally stimulate leukocyte recruitment. There are four defined chemokine subfamilies based on their primary structure, CXC, CC, C, and CX₃C. Monocyte chemoattractant protein (MCP)-1, which belongs to the CC subfamily, regulates the recruitment and activation of inflammatory cells, including monocytes/macrophages and T lymphocytes (8, 9). These inflammatory cells that infiltrate into the liver promote the progression of hepatic fibrosis by releasing various mediators (10). In fact, MCP-1 expression is up-regulated in the livers of patients with active cirrhosis (11), and activated HSCs are predominantly responsible for MCP-1 production (12). MCP-1 is secreted by various types of cultured cells. Among them, rat vascular smooth muscle cells (VSMCs)

Manuscript received July 27, 2004; accepted September 28, 2004.

From the *Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, and †Division of General Medicine, Hiroshima University Medical Hospital, Hiroshima, Japan.

Address for reprint requests: Susumu Tazuma, MD, Division of General Medicine, Hiroshima University Medical Hospital, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan; stazuma@hiroshima-u.ac.jp.

(13) and cardiac fibroblasts (14) are stimulated to produce MCP-1 by Ang II.

A small GTPase, Rho, is thought to trigger the intracellular pathways that lead to the activation of several transcription factors and nuclear signaling. Previous studies have detected RhoA in activated HSC, and Rho signaling pathways play a prominent role in the activation of HSCs (15, 16). Administration of Y-27632, a specific Rho-kinase inhibitor, has an inhibitory effect on the progression of experimental liver fibrosis in animal models (17, 18). Furthermore, Rho and Rho-kinase are involved in Ang II-induced expression of MCP-1 by VSMCs (13).

We hypothesized that Ang II may act on HSC to induce MCP-1 during liver injury, thereby modulating inflammatory cell infiltration and subsequent hepatic fibrosis. In addition, we examined the role of Rho/Rho-kinase in Ang II-mediated production of MCP-1 by LI90 cells, an HSC cell line.

MATERIALS AND METHODS

Animals. AT1a knockout (AT1a KO) mice were established and kindly provided by Dr. Sugaya (19). C57BL/6 mice were obtained from Hiroshima Jikken Doubutsu (Hiroshima, Japan). Both strains of mice had the same genetic background and animals 6–8 weeks old were used in this study. The mice were allowed free access to food and water and were housed at a constant temperature with a 12-hr light/dark cycle during the study period. Liver fibrosis was induced by the subcutaneous injection of CCl₄ (Wako Pure Chemical Industries, Osaka, Japan) at a dose of 1.0 ml/kg (1:1 in mineral oil) twice weekly for 4 weeks. Mice were killed and livers were harvested at 3 days after the last injection. All animal procedures were done according to our institutional guidelines.

Immunohistological Examination. Liver tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 5- μ m-thick sections. Immunohistochemical analysis was routinely performed using either a goat polyclonal antibody for MCP-1 (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) or CD68 (1:50 dilution; Santa Cruz Biotechnology). Several fields per slide were randomly selected for examination, and representative results from three animals are shown.

Cell Culture. LI90 cells (JCRB0160), which were derived from human HSCs (20), were provided by the Japan Health Science Foundation (Tokyo). LI90 cells were grown to confluence in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, Japan) containing 10% fetal bovine serum (FBS; Gibco, Invitrogen, Japan) in uncoated plastic dishes, and then growth arrest was achieved by culture in DMEM without FBS for 2 days before use in the experiments.

RT-PCR. The steady-state level of each messenger RNA (mRNA) was assessed by a semiquantitative polymerase chain reaction (PCR) using GAPDH or β -actin as the housekeeping gene. RNA was isolated with the RNeasy Mini-kit (Qiagen, Germany) according to the manufacturer's instructions. Then single-stranded complementary DNA (cDNA) was synthesized from 1 μ g of RNA using 0.5 nmol of each random primer and subjected to PCR. Subsequently, the

synthesized cDNA was amplified using specific sets of primers for mouse MCP-1 (forward, ATGCAGGTCCCTGTCATG; reverse, GCTTGAGGTGGTTGTGGA) (21), mouse GAPDH (forward, TGAAGGTCCGTGTGAACCGATTGGC; reverse, CATGTAGGCCATGAGGTCCACC AC) (21), human MCP-1 (forward, GACCACCTGGACAAGCAAAC; reverse, CTCAAAACATCCCAGGGTA) (22), human RhoA (forward, CTGGTGATTGTTGGTGATGG; reverse, GCGATCATAATCTTCCTGCC) (23), and human β -actin (forward, GAGCGGGAAATCGTGCCTGACATT; reverse, GATG-GAGTTGAAGGTAGTTTCCTG) (22). The PCR procedure used has been described previously (21–23). An aliquot (10 μ l) of each PCR product was loaded onto a 2% agarose gel and stained with ethidium bromide. Then the band intensities were analyzed by densitometry.

Quantification of MCP-1 Protein by ELISA. Culture medium of nonstimulated LI90 cells or LI90 cells stimulated with Ang II for 2 days was collected and centrifuged at 12,000 rpm for 1 min. The supernatant was stored at -80°C until assay. MCP-1 was measured using a commercial enzyme-linked immunosorbent assay kit (Chemicon International, USA) according to the manufacturer's instructions.

NF- κ B Activity Assay. LI90 cells were stimulated with 10⁻⁷ M Ang II for 1 hr with or without pretreatment using Y-27632 (Calbiochem–Novabiochem, USA) at a concentration of 10⁻⁵ M for 30 min. Nuclear extracts were prepared with a Nuclear Extraction kit (Active Motif, Japan), and the protein content was standardized. Then NF- κ B activity was measured in the nuclear extracts using an NF- κ B P65 Transcription Factor Assay kit (Chemicon International) according to the manufacturer's instruction.

Statistical Analysis. Results are expressed as the mean \pm SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) and *P* < 0.05 was considered to indicate significance.

RESULTS

Hepatic MCP-1 Expression in CCl₄-Treated Mice. RT-PCR revealed the up-regulation of hepatic MCP-1 mRNA expression in CCl₄-treated WT mice, whereas it was negligible in CCl₄-treated and untreated AT1a KO mice (Figure 1). Immunohistochemical analysis also confirmed the enhanced hepatic expression of MCP-1 protein in CCl₄-treated WT mice. After CCl₄ treatment




Fig 1. Steady-state hepatic MCP-1 mRNA expression in WT and AT1a KO mice with or without CCl₄ treatment for 4 weeks. An aliquot of each PCR product was loaded onto a 2% agarose gel and stained with ethidium bromide. Amplification of GAPDH was done to confirm the equal amounts of mRNA in each sample. The result shown here is representative of three independent experiments.




Fig 2. Immunohistochemical staining of MCP-1 in liver tissue from (A) a WT mouse and (B) an AT1a KO mouse after 4 weeks of CCl₄ treatment (1.0 ml/kg). CV, central vein. (Original magnification, $\times 100$.)

for 4 weeks, MCP-1 staining was prominent in the portal tracts and fibrous septa of WT mice (Figure 2A). In contrast, the livers of CCl₄-treated AT1a KO mice showed almost no MCP-1 staining (Figure 2B) and were similar to the livers of the untreated groups (data not shown).

Hepatic CD68-Positive Cells in CCl₄-Treated Mice.

As chemokines are considered to affect the recruitment of inflammatory cells, immunohistochemistry for the activated monocyte/macrophage marker CD68 (the main targets of MCP-1) was performed. In CCl₄-treated WT mice, the number of CD68-expressing cells was markedly increased in the portal tracts (Figure 3A). On the other hand, CCl₄ treatment had little influence on the number of CD68-expressing cells in the livers of AT1a KO mice (Figure 3B). These observations demonstrated that the number of CD68-expressing cells in the liver was associated with the expression of MCP-1.

Effect of Ang II on MCP-1 mRNA Expression.

LI90 cells were stimulated with Ang II at a concentration of 10^{-7} M, and MCP-1 mRNA expression was ex-

amined at the indicated times by semiquantitative PCR. The expression of MCP-1 mRNA was enhanced, reaching a peak at 3 hr and returning to the basal level after 24 hr. The time course of MCP-1 mRNA expression was paralleled by the changes in RhoA mRNA (Figure 4A). Then LI90 cells were incubated with various concentrations of Ang II (10^{-11} to 10^{-5} M) for 3 hr. The expression of MCP-1 mRNA increased dose dependently and showed a pattern similar to that of RhoA mRNA (Figure 4B).

MCP-1 Protein Level in Culture Medium. To assess MCP-1 protein secretion into the culture medium, LI90 cells were stimulated with various concentrations of Ang II with or without Y-27632 pretreatment at a concentration of 10^{-5} M. Ang II dose dependently increased MCP-1 production after 48 hr of stimulation, and a significant difference was seen at a concentration of 10^{-7} or 10^{-5} M. Y-27632 markedly inhibited the secretion of MCP-1 protein induced by Ang II, whereas it had no suppressive effect on FBS-induced MCP-1 secretion (Figure 5).




Fig 3. Distribution of CD68-positive cells in the liver. Immunohistochemical staining for CD68-positive mononuclear cells was performed in liver tissue from (A) a WT mouse and (B) an AT1a KO mouse after 4 weeks of CCl₄ treatment (1.0 ml/kg). CV, central vein. (Original magnification, $\times 100$.)

ANGIOTENSIN II AND HEPATIC INFLAMMATION




Fig 4. Effect of Ang II on MCP-1 mRNA expression by cultured LI90 cells. (A) Serum-starved LI90 cells were treated with 10^{-7} M Ang II at the indicated times, and the changes in Ang II-induced MCP-1 mRNA expression were examined by semiquantitative PCR. (B) Serum-starved LI90 cells were stimulated with Ang II at the indicated concentrations (10^{-11} to 10^{-5} M) for 3 hr, and MCP-1 mRNA expression was examined by semiquantitative PCR. Gels were scanned with a digital image analysis system, the products were quantified, and results are shown relative to the level of the housekeeping gene β -actin. Data from four independent experiments are shown as means \pm SD. * $P < 0.05$ vs. Rho A/ β -actin of serum-free control; # $P < 0.05$ vs. MCP-1/ β -actin of serum-free control.

Effect of Ang II on NF- κ B Activity in LI90 Cells. NF- κ B is the important factor involved in MCP-1 gene transcription in several cell types. To examine whether NF- κ B participated in the induction of MCP-1 in Ang II-stimulated LI90 cells, NF- κ B activity was studied. Growth-arrested LI90 cells were incubated with 10^{-7} M Ang II for 1 hr. In contrast to the up-regulation of MCP-1, Ang II did not activate NF- κ B in LI90 cells (Figure 6).

DISCUSSION

There is accumulating evidence that the RAS is involved in hepatic fibrogenesis. Chronic liver injury up-regulates




Fig 5. Effect of Ang II on MCP-1 secretion into the culture medium. Serum-starved LI90 cells were stimulated for 48 hr with the indicated concentrations of Ang II in the absence or presence of Y-27632 (10^{-5} M). Data from four independent experiments are shown as means \pm SD. * $P < 0.05$ vs. serum-free control. # $P < 0.05$ vs. each group without Y-27632.

key components of the RAS in an animal model of bile duct ligation (6), and RAS blockade ameliorates various types of experimental hepatic fibrosis (2-4). In patients with early chronic hepatitis C, an AT1 receptor antagonist decreased the area of hepatic fibrosis (24). We recently demonstrated that mice lacking the AT1 receptor are protected against CCl₄-induced hepatic fibrosis. Moreover, it was noteworthy that inflammatory infiltrates in the livers




Fig 6. NF- κ B activity in nuclear extracts of Ang II-stimulated LI90 cells. The cells were stimulated using Ang II for 1 hr with or without preincubation of Y-27632 (10^{-5} M). Then nuclear protein was extracted, and NF- κ B activity was estimated. Absorbance values were standardized according to the protein concentration. The absorbance relative to that of the positive control (TNF α -stimulated whole Hela cells) from four independent experiments is shown as the mean \pm SD.

of knockout mice were less severe compared with those in WT mice (5). This observation is in agreement with published data showing that prolonged systemic infusion of Ang II in normal rats induces hepatic inflammation (25). Therefore, there appears to be a close link between Ang II signaling and hepatic tissue inflammation.

MCP-1 is one of the potent chemokines that contributes to the accumulation of inflammatory cells. Since the recruitment of inflammatory cells depends on the expression of chemokines and adhesion molecules, hepatic MCP-1 expression is considered to play an important role in the pathogenesis of chronic hepatitis. MCP-1 levels have been reported to be elevated in the liver by treatment with CCl₄, endotoxin, or alcohol in experimental animals as well as in patients with chronic hepatitis (11, 12, 26, 27). In the present study, we demonstrated that mice lacking the AT1a receptor showed lower expression of MCP-1 and fewer CD68-positive cells in the liver after chronic CCl₄ treatment. These results do not mean the total elimination of hepatic inflammation but confirm that Ang II signaling via AT1a is critical for hepatic expression of MCP-1 and for the recruitment of mononuclear cells into the liver. According to the previous report (28), Kupffer cells play a critical role in the pathogenesis of hepatic inflammation and fibrosis through the release of biologically active mediators. In this regard, Ang II modulates hepatic inflammation via control of MCP-1 expression and subsequent mononuclear cells recruitment.

HSC can amplify inflammation through the release of chemokines such as MCP-1, and the up-regulation of such chemokines further amplifies inflammation during the process of liver injury (29, 30). In this study, we examined whether Ang II induces MCP-1 in cultured LI90 cells. Ang II enhanced the expression of MCP-1 mRNA together

with RhoA mRNA in LI90 cells and, also, stimulated secretion of MCP-1 protein into the culture medium in a dose-dependent manner. Pharmacological blockade of Rho signaling with Y-27632, a specific inhibitor of Rho-kinase, strongly suppressed the Ang II-induced increase in MCP-1 production. The small G protein Rho is a member of the Rho family of small GTPases that also includes Rac and Cdc42. It is understood that Rho has a role in various cell functions, such as the control of cell morphology, proliferation, apoptosis, and regulation of various transcriptional factors. Recently, considerable attention has been paid to the role of Rho in the pathogenesis of hepatic fibrosis. Rho is reported to regulate the activation and proliferation of cultured HSC (15, 16), while administration of Y-27632 inhibits the development of hepatic fibrosis induced by dimethylnitrosamine (17) and CCl₄ (18) in animals. Furthermore, there are several lines of evidence for a close link between Ang II and the Rho signaling pathway. Ang II activates Rho in cultured VSMCs (13) and rat aortic endothelial cells (31), with induction of MCP-1 occurring in the former cell type. Interestingly, we found that Y-27632 did not suppress MCP-1 production when HSC were stimulated with FBS, which contains various growth factors. This suggests that the repressive effect of Y-27632 on MCP-1 production depends on the type of stimulation applied to HSC.

MCP-1 is produced by various types of cells, including HSC, monocytes, fibroblasts (14), and VSMCs (13), in response to a number of stimuli. Since the effects of different stimuli on MCP-1 expression are quite diverse among cell types, transcriptional activation generally seems to depend on an intricate series of regulatory mechanisms. Previous studies have indicated that NF- κ B is the main factor involved in regulating the transcription




Fig 7. Speculated mechanism of how angiotensin II participates in hepatic inflammation after liver injury. Ang II enhances MCP-1 gene expression and synthesis, partly via the Rho signaling pathway, which modulate the recruitment of inflammatory cells into the liver. AT1-R, angiotensin II type1 receptor; HSCs, hepatic stellate cells.

of MCP-1 induced by LPS, IL-1 β , TNF- α , and phorbol esters (32, 33). It was also reported that Ang II promotes MCP-1 expression via activation of NF- κ B in cultured glomerular mesangial cells (34), as well as macrophages and VSMCs (13). Moreover, systemic Ang II infusion increases the DNA-binding activity of NF- κ B in animals (25). Contrary to our expectation, the present study demonstrated that the level of NF- κ B activity in LI90 cells was not altered by Ang II. However, this result is in agreement with the findings of a recent study using primary cultured human HSC (35), so further investigation is needed.

In conclusion, the present study demonstrated that the lack of Ang II signaling reduces the hepatic expression of MCP-1 and recruitment of activated Kupffer cells in a CCl₄-induced hepatic fibrosis model. In cultured LI90 cells, it was also shown that Ang II enhances MCP-1 gene expression and synthesis, partly via the Rho signaling pathway (Figure 7). These findings explain the mechanism by which inhibition of Ang II synthesis or blockade of AT1 signaling can reduce hepatic inflammation and subsequent fibrosis.

ACKNOWLEDGMENTS

This study was partly supported by a grant from the Japanese Ministry of Education, Culture, Sports, Science, and Technology to Dr. Tazuma (No. 12670489).

REFERENCES

1. Bataller R, Gines P, Nicolas JM, Gorbis MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodes J: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. *Gastroenterology* 118:1149-1156, 2000
2. Wei HS, Li DG, Lu HM, Zhan YT, Wang ZR, Huang X, Zhang J, Cheng JL, Xu QF: Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl₄ (4). *World J Gastroenterol* 6:540-545, 2000
3. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE: Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. *Gastroenterology* 121:148-155, 2001
4. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. *Hepatology* 34:745-750, 2001
5. Kanno K, Tazuma S, Chayama K: AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl₄ (4). *Biochem Biophys Res Commun* 308:177-183, 2003
6. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW: Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. *Gastroenterology* 123:1667-1676, 2002
7. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, Colmenero J, Nicolas JM, Jimenez W, Weich N, Gutierrez-Ramos

- JC, Arroyo V, Rodes J: Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. *Gastroenterology* 125:117-125, 2003
8. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B: Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. *FASEB J* 8:1055-1060, 1994
9. Gressner AM: Cytokines and cellular crosstalk involved in the activation of fat-storing cells. *J Hepatol* 22:28-36, 1995
10. Bernuau D, Rogier E, Feldmann G: In situ ultrastructural detection and quantitation of liver mononuclear phagocytes in contact with hepatocytes in chronic type B hepatitis. *Lab Invest* 51:667-674, 1984
11. Narumi S, Tomimaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K, Itoh Y, Okanoue T: Expression of IFN-inducible protein-10 in chronic hepatitis. *J Immunol* 158:5536-5544, 1997
12. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, Gentilini P: Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. *Am J Pathol* 152:423-430, 1998
13. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, Takeya M, Yoshimura T, Takeshita A: Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. *Hypertension* 38:100-104, 2001
14. Omura T, Yoshiyama M, Kim S, Matsumoto R, Nakamura Y, Izumi Y, Ichijo H, Sudo T, Akioka K, Iwao H, Takeuchi K, Yoshikawa J: Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression. *Arterioscler Thromb Vasc Biol* 24:270-275, 2004
15. Yee HF Jr: Rho directs activation-associated changes in rat hepatic stellate cell morphology via regulation of the actin cytoskeleton. *Hepatology* 28:843-850, 1998
16. Kato M, Iwamoto H, Higashi N, Sugimoto R, Uchimura K, Tada S, Sakai H, Nakamura M, Nawata H: Role of Rho small GTP binding protein in the regulation of actin cytoskeleton in hepatic stellate cells. *J Hepatol* 31:91-99, 1999
17. Tada S, Iwamoto H, Nakamura M, Sugimoto R, Enjoji M, Nakashima Y, Nawata H: A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. *J Hepatol* 34:529-536, 2001
18. Murata T, Arai S, Nakamura T, Mori A, Kaido T, Furuyama H, Furumoto K, Nakao T, Isobe N, Imamura M: Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. *J Hepatol* 35:474-481, 2001
19. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A, Uchida H, Sugiura K, Fukuta K, Fukamizu A, Murakami K: Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. *J Biol Chem* 270:18719-18722, 1995
20. Murakami K, Abe T, Miyazawa M, Yamaguchi M, Masuda T, Matsuura T, Nagamori S, Takeuchi K, Abe K, Kyogoku M: Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito (fat-storing) cells. *Lab Invest* 72:731-739, 1995
21. Ousman SS, David S: MIP-1 alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. *J Neurosci* 21:4649-4656, 2001